Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1998-4-29
|
| pubmed:abstractText |
Interstitial cystitis is a severe debilitating bladder disease characterized by unrelenting pelvic pain and urinary frequency. A prospective, double-blind, placebo controlled study of the use of intravesical bacillus Calmette-Guerin (BCG) in the treatment of interstitial cystitis was recently completed with a mean followup of 8 months. Results demonstrated a 60% BCG response rate, compared to a 27% placebo response rate. We now report the long-term followup results of those patients who received intravesical BCG.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0022-5347
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
159
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1483-6; discussion 1486-7
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9554338-Adjuvants, Immunologic,
pubmed-meshheading:9554338-Administration, Intravesical,
pubmed-meshheading:9554338-BCG Vaccine,
pubmed-meshheading:9554338-Cystitis, Interstitial,
pubmed-meshheading:9554338-Female,
pubmed-meshheading:9554338-Follow-Up Studies,
pubmed-meshheading:9554338-Humans,
pubmed-meshheading:9554338-Randomized Controlled Trials as Topic,
pubmed-meshheading:9554338-Treatment Outcome
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
The efficacy of intravesical bacillus Calmette-Guerin in the treatment of interstitial cystitis: long-term followup.
|
| pubmed:affiliation |
Department of Urology, William Beaumont Hospital, Royal Oak, Michigan, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|